Archives

  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-05
  • 2022-04
  • 2021-03
  • 2020-08
  • 2020-07
  • 2020-03
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • br AUTHOR CONTRIBUTIONS br JL PJM and

    2022-05-13


    AUTHOR CONTRIBUTIONS
    JL, PJM and LZP conceived and designed the study. JL, PJM, RY and JEV performed experiments. JL analyzed and interpreted the experi-mental data. MM, JMS and THV scored the TMAs. RY and EXC per-formed the HPLC-MS/MS analysis. YW provided the PDX model. DTSW, RJH and NEF provided clinical data and expertise. JL and LZP wrote the manuscript. All authors read and approved the manuscript. LZP su-pervised the study.
    ACKNOWLEDGMENTS
    We thank all members of the Penn lab for helpful discussions. We especially thank Dr. Carolyn Goard and Melanie Peralta for their assistance with purifying and vali-dating the HMGCR antibody for IHC. We also thank Drs. Robert Bristow and Mathieu Lupien for reagents, and Dr. Miran Kenk, Wenjiang Zhang and Maria Monroy for their technical support. This work was supported by funding from the Canada Research Chairs program (L.Z. Penn), Canadian Institutes of Health Research (FRN: 142263; L.Z. Penn), CIHR Doctoral Research Awards (J. Longo and R. Yu) and Ontario Student Opportunity Trust Fund (J.E. van Leeuwen). This work was also supported by the
    128 MOLECULAR METABOLISM 25 (2019) 119e1302019 University Health Network. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
    www.molecularmetabolism.com
    Princess Margaret Cancer Foundation Hold’em for Life Prostate Cancer Research Fund.
    APPENDIX A. SUPPLEMENTARY DATA
    Supplementary data to this Rosiglitazone article can be found online at https://doi.org/10.1016/j.
    CONFLICTS OF INTEREST
    None declared.
    REFERENCES
    [3] Paller, C.J., Antonarakis, E.S., 2013. Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new di-rections. Clinical Advances in Hematology and Oncology 11(1):14e23.
    [15] Ettinger, S.L., Sobel, R., Whitmore, T.G., Akbari, M., Bradley, D.R., Gleave, M.E., et al., 2004. Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Research 64(6):2212e2221.
    [24] Murtola, T.J., Syvälä, H., Tolonen, T., Helminen, M., Riikonen, J., Koskimäki, J., et al., 2018. Atorvastatin versus placebo for prostate cancer before radical prostatectomy e a randomized, double-blind, placebo-controlled clinical trial. European Urology 74(6):697e701.
    [28] Hao, J., Ci, X., Xue, H., Wu, R., Dong, X., Choi, S.Y.C., et al., 2018. Patient-derived hormone-naive prostate cancer xenograft models reveal growth factor receptor bound protein 10 as an androgen receptor-repressed gene driving the development of castration-resistant prostate cancer. European Urology 73(6): 949e960.
    MOLECULAR METABOLISM 25 (2019) 119e1302019 University Health Network. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 129 www.molecularmetabolism.com
    Original Article
    [35] Tatidis, L., Gruber, A., Vitols, S., 1997. Decreased feedback regulation of low density lipoprotein receptor activity by sterols in leukemic cells from patients with acute myelogenous leukemia. Journal of Lipid Research 38(12):2436e2445.
    [36] Chen, Y., Hughes-Fulford, M., 2001. Human prostate cancer cells lack feed-back regulation of low-density lipoprotein receptor and its regulator, SREBP2. International Journal of Cancer 91(1):41e45.
    [37] Li, X., Chen, Y., Hu, P., Huang, W., 2014. Fatostatin displays high antitumor activity in prostate cancer by blocking SREBP-regulated metabolic pathways and androgen receptor signaling. Molecular Cancer Therapeutics 13(4): 855e866.
    opportunity breast cancer trial. Breast Cancer Research and Treatment 138(2):499e508.
    130 MOLECULAR METABOLISM 25 (2019) 119e1302019 University Health Network. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).